AmerisourceBergen stock soars to all-time high of $271.17

AmerisourceBergen (NYSE:COR) Corporation (NYSE: ABC), a $52 billion market cap healthcare giant, has reached a new pinnacle as its stock price soared to an all-time high of $271.17, marking a significant milestone for the pharmaceutical sourcing and distribution services company. According to InvestingPro data, the company maintains a GOOD financial health score. This peak comes amidst a robust year for AmerisourceBergen, which has delivered even stronger recent performance with a 20.46% gain over the past six months and a 19.76% rise year-to-date. Investors and industry analysts alike are closely monitoring the company’s performance, as it continues to navigate the dynamic healthcare landscape and capitalize on growth opportunities. The all-time high represents not only a triumph for AmerisourceBergen but also signals confidence from the market in the company’s strategic direction and its potential for sustained growth. InvestingPro analysis suggests the stock remains slightly undervalued, with additional insights available in the comprehensive Pro Research Report.

In other recent news, Cencora, Inc. has adjusted its fiscal year 2025 earnings per share (EPS) guidance following the acquisition of Retina Consultants of America. The transaction, valued at $4.4 billion, resulted in an upward revision of Cencora’s adjusted EPS to a range of $15.15 to $15.45, from the previous estimate of $14.80 to $15.10. This acquisition is expected to enhance Cencora’s position in specialty medical services and expand its management services organization solutions. Additionally, Leerink Partners has increased Cencora’s stock price target to $301, maintaining an Outperform rating, influenced by the company’s strong performance in its pharmaceutical distribution segment. The updated guidance for U.S. Healthcare EBIT showed a nearly 4% rise, further supporting Leerink’s positive outlook. In corporate governance news, Cencora announced the retirement of board members Richard W. Gochnauer and Kathleen W. Hyle, effective at the next Annual Meeting of Stockholders. Meanwhile, shareholders recently approved the executive compensation package and elected directors during the company’s Annual Meeting. The ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year 2025 was also confirmed.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.